Chen, Christine I <br/><br/>
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Apr 2007 
 - 1570-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2006.07.8659  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Ambulatory Care<br/>Boronic Acids--adverse effects<br/>Bortezomib<br/>Canada<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Infusions, Intravenous<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Recurrence, Local--diagnosis<br/>Probability<br/>Protease Inhibitors--adverse effects<br/>Pyrazines--adverse effects<br/>Risk Assessment<br/>Salvage Therapy<br/>Severity of Illness Index<br/>Survival Rate<br/>Treatment Outcome<br/>Waldenstrom Macroglobulinemia--diagnosis